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Abstract
A proteoform is a defined form of a protein derived from a given gene with a specific amino acid 
sequence and localized post-translational modifications. In top-down proteomic analyses, 
proteoforms are identified and quantified through mass spectrometric analysis of intact proteins. 
Recent technological developments have enabled comprehensive proteoform analyses in complex 
samples, and an increasing number of laboratories are adopting top-down proteomic workflows. In 
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this review, we outline some recent advances and discuss current challenges and future directions 
for the field.
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I. Introduction
Much of the biochemical diversity in cells occurs at the protein level. A proteoform consists 
of a defined amino acid sequence with localized modifications (Figure 1).1 Proteoforms 
arise as a result of collective biological processes including amino acid variation, alternative 
RNA splicing, post-translation modification, and post-translational cleavage. Proteoforms 
derived from the same gene make up a proteoform family.2 The biological function of 
different proteoforms can vary greatly, even among proteoforms belonging to the same 
family.3,4 Therefore, the identification and quantification of specific proteoforms is vital to 
the understanding of a biological system.
Mass spectrometry (MS) has proven to be a valuable tool in the study of protein and 
proteoform biology.5–7 MS-based proteomics can be divided into two broad categories: top-
down and bottom-up (Figure 2). In bottom-up proteomics, proteins are digested by a 
protease to generate peptides that are analyzed via tandem MS.8 Because peptides are 
directly detected instead of proteins, protein inference must be used to reconstruct the 
proteins hypothesized to exist in the sample.9 Since proteins often contain homologous 
sequence regions, a number of identified peptides can reasonably emanate from more than 
one protein. These shared peptides significantly complicate the protein inference process.10 
The loss of information caused by the digestion of proteins, such as the relationship between 
the amino acid sequence and the PTMs belonging to a specific proteoform, prevents bottom-
up proteomic analysis from identifying proteoforms.
Top-down proteomics directly analyzes intact proteins.10–15 The relationship between amino 
acid sequence and PTMs is preserved and proteoforms can be characterized, providing a 
proteoform-specific understanding of biological phenomena. Recent reviews have covered 
sample preparation and mass spectrometry instrumentation techniques for top-down 
proteomic analyses.7,11–13 Top-down proteomic experiments are subject to many analytical 
challenges owing to the low abundance of many proteoforms and the low signal-to-noise 
(S/N) ratios inherent to mass measurement of large molecules.16 Data analysis of 
proteoforms is also challenging due to the complexity of intact and fragmented proteoform 
MS data. Co-elution of proteoforms in online LC-MS experiments further compounds these 
issues.
This review highlights recent advances in the field of top-down proteomics that enable the 
analysis of complex samples and the identification of thousands of proteoforms.17–19 First, 
we define terminology used within proteomics. Next, we discuss recent developments in 
online and offline intact protein separation techniques, including size-based separations, 
reversed-phase liquid chromatography (RPLC), and capillary zone electrophoresis (CZE). 
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We then review techniques for proteoform identification and quantification as well as several 
different software tools including TDPortal20, MSPathFinder21, TopPIC22, Proteoform 
Suite23, MASH Suite24, and MetaMorpheus25. Finally, we discuss current challenges and 
future directions specific to the analysis of proteoforms.
II. Proteomics Terminology
The language used in proteomics has significantly evolved over the years. Until recently, 
there was no established term to refer to a specific arrangement of amino acids and PTMs1; 
protein, protein form, and protein isoform were all used. In this section, we provide 
definitions for terms used in this review (Table 1).
A protein refers to a linear sequence of amino acids. PTMs may or may not be present, but a 
specific molecular form is not implied when the term protein is used. It is common to 
employ a one-protein-per-gene convention.26 For example, the human genome contains 
~20,000 genes, and the corresponding canonical human protein database from UniProt27 
contains ~20,000 protein sequences. Unfortunately, this is a crude approximation for the 
complexity of the human proteome. Genes are transcribed into pre-mRNA molecules, which 
are spliced into any number of different isoforms, each of which is translated into a unique 
protein. The UniProt definition of protein isoform is a member of a set of proteins from the 
same gene or gene family that arise from alternative splicing or variable promoter usage 
(https://www.uniprot.org/help/canonical_and_isoforms). Bottom-up proteomic analyses 
typically use a canonical protein database; including multiple isoforms per gene increases 
sequence redundancy in the database, complicating protein inference. Not including protein 
isoforms in the database, however, renders a large portion of the actual proteome invisible to 
identification.
In bottom-up proteomics, the presence of a protein can be confidently inferred only when a 
peptide unique to that protein is identified.9 There can be high sequence homology between 
proteins and certainly between protein isoforms. A protein group is a collection of proteins 
that are indistinguishable based on the peptides identified.9
A proteoform is a defined sequence of amino acids with localized modifications. One gene 
can yield a wide variety of proteoforms.1 The term proteoform family refers to all 
proteoforms derived from a single gene, including protein products from all mRNA splice 
forms, post-translational processing, and PTMs.2 There is a desire to classify proteoforms 
within a gene-centric system, which creates a major need in top-down proteomics for a 
unified proteoform nomenclature convention. ProForma, a human-and machine-readable 
nomenclature for writing proteoform sequences, was created to meet this need.28 An open-
source parser/writer application called the TopDown Software Development Kit (SDK) has 
been developed (http://github.com/topdownproteomics/sdk) to facilitate the passing of 
results between software programs.
The term proteoform spectrum match (PrSM) is used to describe a search algorithm’s match 
between a proteoform identification and an observed tandem mass spectrum. This is 
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analogous to the term peptide spectrum match (PSM) frequently used in bottom-up 
proteomics.
III. Separation of Proteoforms
Overview
Separating proteoforms is important because co-elution of proteoforms is detrimental to 
proteoform identification in several ways. Many high-resolution mass spectrometers have a 
finite ability to detect proteoforms due to limited charge capacity, so low-abundance 
proteoforms are often not observed without enrichment. Additionally, co-isolation of 
multiple proteoforms prior to fragmentation complicates data analysis and proteoform 
identification. MS2 spectra of intact proteins often contain many overlapping fragments that 
are difficult to resolve. This necessitates high resolving power as well as the averaging of 
considerable numbers of spectra to improve S/N. These obstacles can limit analyses to 
proteoforms with molecular weights below 30 kDa, rendering more than half of the human 
proteome inaccessible.
A wide variety of fractionation and separation techniques have been combined to reduce the 
complexity of samples delivered to the mass spectrometer.11, 29 Here, we highlight such 
techniques (summarized in Table 2), including size-based separations, high-and low-pH 
reversed-phase liquid chromatography (RPLC), and capillary zone electrophoresis (CZE). 
Additionally, other chromatography modes, such as hydrophobic interaction 
chromatography (HIC)30, 31 and ion exchange chromatography (IEX)32, have been reported 
(see Chen et al).11 Another related and emerging separation in top-down proteomics is ion 
mobility spectrometry.33, 34
Size-Based Separation
Top-down analysis of larger proteoforms is challenging due to the inverse relationship 
between S/N and proteoform mass.16, 35 Inherently low S/N combined with the co-elution of 
smaller proteoforms compromises observation of large proteoforms without prior 
fractionation. Tran et al. pioneered the gel-eluted liquid fraction entrapment electrophoresis 
(GELFrEE) technique, which achieves high-resolution size-based separation of proteoforms.
36
 GELFrEE has been coupled with other separation techniques to achieve deep coverage.
19, 37, 38
 GELFrEE has also been adapted for native-state size separations to separate protein 
complexes39 and preserve higher order structure.40
Size exclusion chromatography (SEC) is an appealing option for fractionation because of its 
compatibility with a variety of eluents, including those which are MS-compatible (e.g. 1 % 
formic acid, ammonium acetate).41 Solubilizing intact proteins in MS-compatible buffers is 
one major challenge at the front-end of top-down proteomic workflows, especially for 
membrane proteins which are inherently hydrophobic.42 Although acid-labile surfactants 
such as RapiGest™ (RG, also known as ALS, Waters)43, 44, ProteaseMax™ (PM, 
Promega)45, and the recently developed MS-compatible slowly-degradable surfactant 
(MasDeS)46 have been proven to be highly effective for bottom-up proteomics, they have yet 
to be demonstrated as directly compatible with intact protein MS analysis.
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Ge and co-workers recently introduced serial size exclusion chromatography (sSEC), which 
combines multiple matrix pore sizes for separation of complex protein mixtures in MS-
compatible buffers.47 SEC is a non-adsorptive mode of liquid chromatography that sorts 
molecules based on their size and differential access to matrix pore volume.48, 49 The 
combination of SEC with different pore sizes provides an extension of molecular weight 
fractionation range and higher-resolution separation of proteins compared to conventional 
SEC. sSEC coupled to RPLC-quadrupole-time-of-flight mass spectrometry provided 
improved proteome coverage, with a 15-fold improvement in the observation of proteoforms 
>60 kDa compared to one-dimensional RPLC alone and enabled the observation of large 
proteoforms (up to 223 kDa). More recently, the Ge lab paired sSEC with FT-ICR MS 
analysis to enable sequence characterization of large proteoforms without RPLC separation 
or protein purification.50
Reversed-phase liquid chromatography separation
RPLC is the most prevalent approach for complex intact protein sample separation and 
fractionation.12, 51–54 Various improvements such as smaller particle sizes and longer 
columns have been developed to increase the peak capacity for deeper proteome analysis. 
Smaller packing particles provide more uniform packing structure in columns, which 
improves peak symmetry and separation resolution.55, 56 However, as particle size decreases, 
the pressure required to provide sufficient flow increases dramatically.
Longer columns and higher-pressure pumps are also used to improve peak capacity. Recent 
studies suggest that elution peak widths with longer columns do not increase remarkably 
with longer separation windows (i.e., 200 minutes or longer).57 Therefore, under ultra-high 
pressure (10,000 psi) and long elution gradients, column length may have a greater impact 
on the separation resolution than particle size. Recently, Shen et al. identified ~900 
proteoforms from S. oneidensis lysate using long-column RPLC-MS analysis.58 Similarly, 
Ansong and coworkers utilized a long C5 capillary column (80 cm) and identified 1,665 
Salmonella proteoforms.52 Longer RPLC columns and high-pressure systems can also be 
applied to separate proteoforms with high sequence homology. Wang and coworkers 
reported the long column ultrahigh pressure liquid chromatography (UPLC) top-down 
analysis of human serum autoantibodies that are complex with highly homologous clonal 
sequences. They identified 47 light chains and 16 heavy chains in the SLE patient serum, 
providing the first “bird’s-eye” view of the complexity of human serum autoantibodies.59 
One major limitation of long column UPLC separation for top-down proteomics is a lack of 
commercially-available long columns. In-house packing of long columns often requires 
customized equipment and expertise for uniform packing.
Wang and co-workers recently reported a two-dimensional (2D) separation using high-pH 
and low-pH RPLC for top-down proteomics.57 The orthogonality between these two 
approaches was first demonstrated by the observation of different elution orders under 
different pH conditions using the same set of standard proteins. Different proteoform elution 
behaviors were also observed between low-pH and high-pH RPLC separation of complex 
samples (e.g., E. coli cell lysate). The orthogonality between high-pH and low-pH 
conditions may be related to different polarities of five amino acids (Glu, Asp, Arg, His, and 
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Lys) under different pH conditions.60 Proteoform retention behaviors are less molecular 
weight dependent under high-pH conditions, which may be due to different distributions of 
charges in the proteoform primary structure.57, 61–63 A potential drawback is that some 
proteins are less charged under high-pH conditions and cannot be efficiently eluted from the 
column.
Offline 2D-RPLC fractionation is relatively simple because fractions from the high-pH 
column are concentrated using vacuum drying prior to injection onto the low-pH column. 
When performing online 2D-RPLC, an additional dilution step must be incorporated due to 
the high organic solvent content of the eluent from the high-pH separation. One successful 
application of this 2D high-pH and low-pH approach resulted in the identification of 886 
proteoforms in E. coli cell lysate, which is a significant improvement over the 328 
proteoforms identified using one-dimensional low-pH RPLC separation.57
Capillary Zone Electrophoresis
CZE is a method of separating proteoforms by differences in electrophoretic mobility that 
does not require a stationary phase. It is orthogonal to RPLC because the separation is based 
on size and charge rather than hydrophobicity. CZE-MS/MS has recently attracted attention 
for top-down proteomics due to major improvements in the CZE-MS interface64–66, the 
coating on the inner wall of separation capillaries67, and sample stacking methods for online 
concentration.68–70 In 1996, the McLafferty group detected attomole amounts of intact 
proteins using CZE-MS and identified carbonic anhydrase in a human red blood cell lysate 
using MS/MS.71 More recently, the Yates group reported nearly 300 proteoform 
identifications from Pyrococcus furiosus lysate using RPLC-CZE-MS/MS.72 The Yates 
group also showed that CZE-MS provided comparable S/N ratios to RPLC-MS for 
characterization of a protein complex with 100-fold less sample consumption.73 The 
Dovichi group has demonstrated 600 proteoform identifications from yeast lysate using 
RPLC-CZE-MS/MS.74 The Kelleher group has also demonstrated the potential of CZE-
MS/MS for top-down identification of large proteins.75
Two major issues impede the use of CZE-MS/MS for large-scale top-down proteomics. 
First, the sample loading volume of CZE is low, typically 1% of the total capillary volume. 
For example, the typical sample loading volume of a fused silica capillary with a 50-μm 
inner diameter and a 1 -meter length is approximately 20 nL, which is 2 to 3 orders of 
magnitude lower than the volume of sample used in nanoflow RPLC. The sample loading 
volume of CZE must be increased to enable better characterization of low-abundance 
proteoforms in complex samples. Second, CZE is well known for its fast separation of 
various analytes and narrow separation window (typically less than 30 minutes). When 
analyzing complex mixtures of proteoforms, however, a longer separation window is 
desirable because it allows the mass spectrometer to acquire a larger number of MS and 
MS/MS spectra, resulting in more proteoform identifications.
The Sun group recently made progress towards increasing the sample loading volume and 
the separation window of CZE. They achieved a 90-min separation window and microliter-
scale sample loading volume for CZE-MS/MS analysis of an E. coli cell lysate and 
identified 600 proteoforms in a single run.76 To facilitate the wide separation window and 
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increased sample volume, a separation capillary with a high-quality neutral coating on its 
inner wall and a highly efficient protein stacking method based on a dynamic pH junction 
principle were utilized. They also coupled SEC-RPLC to CZE-MS/MS and identified nearly 
6,000 proteoforms and 850 proteoform families, which is one of the largest reported top-
down proteomic datasets thus far.18 A detailed protocol for CZE-MS/MS-based top-down 
proteomics has been provided to facilitate adoption of this technique.77 More recently, the 
Sun lab developed an SEC-CZE-MS/MS system for native top-down proteomics which 
identified 23 protein complexes in E. coli.78 This work showed the first example of native 
top-down proteomic analysis of a complex proteome using online liquid-phase separation.
There are still at least two concerns about using CZE-MS/MS for large-scale top-down 
proteomics. First, it is still challenging to make high-quality neutral coatings on the inner 
wall of the separation capillary in a reproducible manner. Second, the separation window of 
CZE needs to be increased further. When a 1-meter separation capillary with a high-quality 
neutral coating and a 30 kV voltage were employed for CZE separation of proteoforms, the 
separation window was about 90 min.76 The most advanced RPLC proteoform separation 
with a 1-meter long column has reached an 800-min separation window.58
IV. Informatics Tools for Proteoform Identification
Proteoform Identification
What does it mean to identify a proteoform? There is not currently a unified metric for 
calling a proteoform identified. Different manuscripts utilize different levels of 
characterization or false discovery rates. Top-down MS analyses typically identify 
proteoforms by measurement of the proteoform’s intact mass and the observed MS/MS 
fragment peaks. Search software programs select the best matching theoretical proteoform 
from a set of candidates, and give this match a score and a measure of statistical confidence.
7
 Complete sequence coverage of the proteoform is almost never achieved with these 
analyses. Instead, only a subset of theoretical fragments matches to observed fragments. If 
PTMs are present on the proteoform, they are best localized with fragment ions containing 
the modified amino acid residue, which are only observed a fraction of the time. More work 
is needed to yield greater sequence coverage and confidence in proteoform identifications. 
When a count of identified proteoforms is stated in this review, readers are encouraged to 
consult the original source material for the authors’ threshold for a proteoform to be 
considered identified. There has not yet been a comprehensive analysis comparing the 
identification thresholds of available top-down software tools and how this affects 
proteoform identification results. We describe below several freely available software tools 
for the identification of proteoforms (see summary in Table 3). Many of these tools have 
publicly available source code, which provides the community complete access to and 
understanding of the tool.
TDPortal
Although ProSightPTM versions 179 and 280 are still among the most widely cited top-down 
search tools, the National Resource for Translational and Developmental Proteomics at 
Northwestern University (NU) now also maintains the TDPortal. This service provides top-
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down protein and proteoform identification and label-free intensity values needed for 
relative proteoform quantification. Several reference proteome databases are provided. 
Search results include truncated and modified proteoforms. The service presents a 
Galaxy81–83 frontend that allows users to queue search jobs, resulting in rapid search times. 
Results are returned in .tdreport files which can be viewed with the freely available 
TDViewer application available at http://topdownviewer.northwestern.edu. TDPortal is free 
to academic users and can be requested for use at http://nrtdp.northwestern.edu/tdportal-
request.
TopPIC
TopPIC (Top-down mass spectrometry-based Proteoform Identification and 
Characterization) excels in identifying proteoforms with unknown alterations (PTMs and 
post-translational processing) in a blind mode.22 TopPIC uses indexes of fragment 
masses84, 85 to quickly filter candidate protein sequences in a database. TopPIC then 
performs spectrum alignment86–88 to match experimental spectra to database sequences and 
finally uses a generating function method89 to estimate the statistical significance for each 
identification. It can further match unknown mass shifts in identified PrSMs to common 
PTMs provided by the user and localize them using a Bayesian model.90
TopPIC identifies proteoforms using three search modes. The first mode is analogous to no-
enzyme searches in bottom-up MS. Unknown alterations, except for terminal truncations, 
are excluded from the database search. The second mode is a combination of the no-enzyme 
search and an open database search91, in which one unknown mass shift is allowed per 
identified proteoform. The third mode uses spectrum alignment to identify proteoforms with 
two unknown mass shifts. The algorithm for this mode utilizes internal proteoform 
fragments without alterations for protein sequence filtering and spectrum alignment. The 
internal fragment-based filtering method is used to reduce the search space, and the 
alignment method identifies a proteoform by connecting several unmodified protein 
segments, which is similar to the sequence similarity search algorithm in FASTA.92 TopPIC 
is freely available at http://proteomics.informatics.iupui.edu/software/toppic/.
TopMG
TopMG93 (Top-down mass spectrometry-based proteoform identification using Mass Graph) 
is a software tool for identification of ultra-modified proteoforms with variable PTMs and 
unknown alterations. One important challenge in identifying ultra-modified proteoforms is 
the combinatorial explosion of PTM patterns in a long protein. In TopMG, all proteoforms 
of a protein with variable PTMs are efficiently represented by a mass graph, which is aligned 
with a query spectrum to identify a modified proteoform that best explains the fragment 
masses in the spectrum.
TopMG also incorporates efficient algorithms for filtering protein sequences and estimating 
the statistical significance of identifications. Because a proteoform with multiple PTMs 
often lacks a long unmodified protein fragment, a protein sequence filtering method based 
on unmodified protein fragments becomes inefficient. To obtain long unmodified protein 
fragments, an approximate spectrum-based method is used to remove one or two PTM sites 
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in query spectra by shifting fragment masses to cancel out mass shifts introduced by PTMs.
94
 Because many proteoforms of a protein are almost the same except for PTM sites, it is a 
challenging problem to accurately estimate the proteoform-level statistical significance of 
identifications. TopMG reports protein-level E-values of identifications by combining a 
Markov chain Monte Carlo method and a fast algorithm for estimating similarity scores 
between query spectra and proteins.95 TopMG is freely available at http://
proteomics.informatics.iupui.edu/software/toppic/.
Proteoform Suite
Not all proteoforms observed in the MS1 spectra are able to be selected for fragmentation by 
the mass spectrometer in a typical data-dependent top-down workflow.74, 96, 97 The MS2 
resolution and ion fillings require long scan times, so only two to three proteoforms are 
selected for fragmentation following each MS1 spectrum. Since proteoform 
chromatographic peaks are on the order of a minute long, there are only a few opportunities 
to fragment each eluting proteoform. The problem is further exacerbated by different charge 
states of the same proteoform being selected for fragmentation. As a result, many 
proteoforms observed in the MS1 spectra are not selected for fragmentation. Additionally, 
many fragmentation events do not result in a successful identification.
The Smith lab recently developed Proteoform Suite23, which identifies proteoforms 
observed in MS1 spectra using the observed intact mass. Proteoform masses from 
deconvoluted MS1 spectra are compared to a database of theoretical proteoform masses as 
well as to other experimental masses to form “proteoform relations”. Proteoform relations 
are mass differences corresponding to a known PTM, an amino acid, or combinations 
thereof. Proteoform families are subsequently constructed by grouping together all 
proteoforms connected to one another in a proteoform relation. The results are visualized as 
a network of proteoforms, where circles represent proteoform masses and lines connecting 
circles represent proteoform relations corresponding to a mass difference (Figure 3). A 
challenge in intact-mass analysis is that the specific arrangement of amino acids is less 
confidently determined than when fragmentation is utilized, and PTMs are not able to be 
localized to specific residues.
Recently, Proteoform Suite was augmented to enable the input of top-down MS/MS 
identifications. Additional identifications can be made by comparing the masses of 
proteoforms identified by MS/MS to unidentified proteoform masses observed in the MS1 
spectra. Using intact mass to identify additional proteoforms in a top-down analysis of 
fractionated yeast lysate resulted in an approximately 40% increase in the number of 
proteoform identifications compared to MS/MS analysis alone.98 In a subsequent study, this 
intact-mass approach was applied to a mammalian system of reduced complexity: 
mitochondrial proteins from mouse myoblasts and differentiated myotubes.99 A similar 
~40% increase in the number of proteoform identifications was observed compared to top-
down MS/MS data analysis alone. Proteoform Suite also determined statistically significant 
proteoform abundance changes across myoblast and myotube cell types. Proteoform Suite 
automates identification and quantification of proteoforms observed in MS1 spectra as well 
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as the construction and visualization of proteoform families. Proteoform Suite is open source 
and freely available at http://github.com/smith-chem-wisc/ProteoformSuite.
MetaMorpheus
MetaMorpheus25 is an integrated bottom-up and top-down software program for 
identification of peptides and proteoforms in high-resolution data-dependent mass 
spectrometry experiments. The search algorithm begins by deconvoluting the isolated m/z 
window of each MS1 scan into monoisotopic masses. In addition to providing a highly 
accurate precursor mass for theoretical proteoform selections, this deconvolution process 
also provides an opportunity to reveal multiple co-fragmented precursors, so MetaMorpheus 
can identify multiple peptides/proteoforms from a single tandem mass spectrum. A 
theoretical set of proteoforms is constructed from the user-supplied protein database. PTM 
annotations obtained from UniProt are used by MetaMorpheus. In practice, the deconvoluted 
monoisotopic mass can be incorrectly estimated by several Daltons (see Deconvolution 
section); MetaMorpheus compensates for these monoisotopic mass errors by allowing mass 
differences at approximately 1 Da spacings. After determining the MS2 scan’s precursor 
mass(es), the MS2 spectrum itself is deconvoluted. Each valid theoretical proteoform for the 
scan is fragmented in silico and matched against the spectrum’s deconvoluted masses; the 
score of the PrSM is the number of matched fragment ions plus the fraction of the TIC 
belonging to the matched set of peaks (e.g., a score of 74.65 means 74 fragments matched, 
which composed 65% of the MS2 TIC). The false-discovery rate of a dataset is estimated 
using the target-decoy approach.100
Global PTM Discovery101 (G-PTM-D) is a strategy used by MetaMorpheus25 to identify 
PTM-containing peptides in bottom-up proteomics. It has been extended to top-down 
analysis to identify proteoforms with unknown PTMs. Briefly, a catalog of known PTM 
masses is used as accepted mass differences, much like the monoisotopic mass error strategy 
described above. If a PrSM’s theoretical mass differs from the experimental mass by a 
known PTM’s mass, the PTM is then annotated in the database. A second-pass search with 
the annotated database is then performed to estimate the FDR. One advantage of 
MetaMorpheus is that the G-PTM-D process can also be performed on a bottom-up sample. 
The resulting database can then be used in a subsequent top-down search for proteoform 
identification.102 This is advantageous because proteome coverage is deeper in bottom-up. 
Observation of PTMs in both bottom-up and top-down data from the sample provides 
improved confidence in PTM localization.
MetaMorpheus features include mass-calibration, open-mass searches, identification of co-
isolated analytes, and automated spectrum annotation, which assists in manual evaluation of 
PTM assignments. MetaMorpheus is open source and freely available at http://github.com/
smith-chem-wisc/MetaMorpheus.
MSPathFinder
MSPathFinder is a tool for spectrum identification and label-free quantification of top-down 
proteomic data.21 It is open source and freely available at http://github.com/PNNL-Comp-
Mass spec/Informed-Proteomics/. The goal of the tool was to address two significant 
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challenges in top-down proteomics: obtaining the correct monoisotopic mass and efficient 
searching of modified proteoforms.
Identifying the correct monoisotopic mass is essential to an efficient and accurate 
identification algorithm. MSPathFinder addresses this challenge by simultaneously 
integrating data from all ions and across the LC time scale to boost signal intensity and 
improve the shape of the isotope profile. This method significantly improved monoisotopic 
mass determination, as evidenced by a greater number of monoisotopic masses being present 
in replicate data acquisitions.
The second focus of MSPathFinder is to efficiently explore the combinatorial search space 
of proteoforms with post-translational modifications. MSPathFinder addresses this challenge 
with a sequence graph. This compact graph represents all possible modification sites within 
a protein and takes advantage of the fact that many different proteoforms (different PTM 
placements) share most of their fragment ions. This approach allows the algorithm to score 
various fragment ions much more efficiently and reduces the search time by several orders 
of magnitude.
MASH Suite
The Ge research group recently developed a comprehensive and user-friendly software tool, 
MASH Suite Pro, with multifaceted functionality for data analysis in top-down proteomics 
to enable researchers to perform proteoform identification, quantification, and 
characterization with visual validation.24 This software provides an intuitive interface. Users 
can import deconvolution and protein searching results into MASH Suite Pro for manual 
validation of computational outputs. This function allows users to perform manual 
correction of charge states and isotopic masses of fragment ions for comprehensive 
characterization of sequence variations and PTM sites.103 The software also offers 
quantitative tools to evaluate the relative abundances of different proteoforms under various 
experimental conditions.104
Public Proteoform Repository
The Consortium for Top-Down Proteomics has taken on the task of organizing 
experimentally verified biological proteoforms and providing them unique identifiers. Called 
PFR, or Proteoform Record, the PFR is a durable identifier which uniquely identifies a 
proteoform. The CTDP’s Proteoform Repository can be accessed at http://
atlas.topdownproteomics.org/. All laboratories with interest in top-down proteomics are 
encouraged to submit their experimentally verified proteoform discoveries to this repository.
V. Quantification of Proteoforms
Proteoform-level abundance changes can be determined using several different 
quantification strategies. Here, we describe three strategies for the large-scale measurement 
of the relative abundance of proteoforms. Label-free quantification (LFQ) uses 
measurements of MS1 chromatographic peak height or area.105 In stable isotope labeling of 
amino acids in cell culture (SILAC), each sample is cultured using multiple isotopic forms 
of an amino acid that differ in mass.106 The MS1 intensity ratio of the two isotopic forms 
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provides the relative quantitative difference of the proteoform between samples. Finally, in 
Tandem Mass Tag (TMT), proteoforms are labelled on the N-terminus and on side-chain 
amino groups.107 Each sample is labeled with a separate tag with a unique reporter ion mass. 
The intensities of the TMT reporter ions in fragmentation spectra provide a measure of 
proteoform abundance.
Because the S/N ratios of intact proteins are much lower16 and the chromatographic 
separations are typically less reproducible than in bottom-up108, the quantification of 
proteoforms is technically challenging. However, protein inference is a major problem in 
bottom-up protein quantification.9 Because the identification of the proteins is inferred from 
the observed peptides, the quantification of the protein is also inferred from its constituent 
peptides. In top-down, protein inference is not required, which makes direct proteoform 
quantification possible. The information uncovered in top-down quantification – the 
abundance changes for the specific proteoforms in the system – is important to biological 
understanding.
Label-free quantification (LFQ)
Labeling reagents are not needed in LFQ, so it can be applied to samples not grown in cell 
culture, such as patient tissue samples. LFQ has been applied to several larger scale studies 
of proteoform abundance changes across two conditions.20, 99, 105, 109–111 The Kelleher lab 
first demonstrated this technique using yeast mutant vs. wild-type strains and quantified over 
800 proteoforms. This study implemented a hierarchical linear model to account for sources 
of variation when determining proteoforms with statistically significant changes across 
biological conditions.110 The approach was subsequently used to quantify over 1000 human 
proteoforms in fibroblasts with and without induced senescence; quantitative mass targets 
are determined and MS2 verified identification is attempted.112 The Smith lab has also 
recently implemented a label-free quantification strategy in Proteoform Suite, where the 
differences in abundance of observed masses are determined across two conditions.99 
Proteoform Suite was used to quantify mouse mitochondrial proteoforms in myoblasts and 
differentiated myotubes and determined 129 proteoforms with statistically significant 
abundance changes. LFQ has also been applied in targeted approaches to quantify 
proteoforms from a specific proteoform family across conditions.12, 113, 114
A major challenge in top-down LFQ is the necessity of reproducible sample handling across 
replicates to ensure that observed changes in intensity are biological and not artefactual. A 
second major challenge for LFQ of proteoforms occurs from sample fractionation. High 
levels of fractionation are necessary to facilitate the identification of less abundant 
proteoforms. However, proteoforms can be split between multiple fractions. One response to 
this is the summation of proteoform signal across all fractions in which it appears prior to 
comparison between conditions. Unfortunately, sample handling and measurement artifacts 
can occur across fractions or replicates.
Stable Isotope Labeling of Amino Acids in Cell Culture (SILAC)
In SILAC labeling, proteoform samples from different conditions are cultured separately but 
mixed at the earliest possible point in the workflow, allowing similar sample handling 
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throughout preparation, fractionation, and MS analysis stages.115 MS1 intensities of the two 
co-eluting isotopic forms are used to determine abundance differences of proteoforms 
between conditions. SILAC labeling results in lower quantitative variation compared to LFQ 
because of the uniform sample handling for each labelled form.
NeuCode labeling, a variant of SILAC, employs isotopic forms of lysine where the mass 
difference is only a few mDa.116–118 NeuCode quantification has been applied to top-down 
analysis.118 Measurement of the ratio of isotopic forms provides the relative abundance. The 
Smith lab recently used NeuCode isotopic labeling to identify proteoforms by intact mass 
and number of lysine residues, as the space between a proteoform’s light and heavy isotopic 
forms is directly proportional to its number of lysines.2 Proteoform Suite was used to 
identify 638 yeast proteoforms and determine that 64 experimental proteoforms exhibited 
statistically significant changes between normal and salt-stress conditions.23
There are several major challenges with using SILAC labeling in top-down proteomics. 
There is a decreasing likelihood of labeling the entire proteoform with the isotopic label as 
the number of residues in the proteoform increases. Additionally, the presence of two sets of 
isotopic envelopes for a given proteoform complicates the spectra and data analysis.
Tandem Mass Tag (TMT)
Isobaric chemical tags, such as isobaric tagging for relative and absolute quantification 
(iTRAQ)119 and tandem mass tags (TMT)107, have been developed to simultaneously 
identify and quantify proteins using tandem MS. The labeling reagents consist of an amine 
reactive group, a mass normalizer, and a mass reporter. The mass normalizer and the mass 
reporter carry isotopes in different combinations so that the mass reporters have different 
masses while the intact mass of reagents remains the same. Isobaric labeling techniques have 
been widely applied in bottom-up proteomics120, 121, and they have been utilized to label 
intact proteins122–124; however, until recently, only a few attempts on standard proteins have 
been made in top-down MS.125 Recently, Yu and co-workers developed a protein-level TMT 
labeling platform for intact proteoform quantification in complex protein samples (e.g., E. 
coli cell lysate) (manuscript in preparation). The HCD-based fragmentation approach was 
used to generate the reporter ions for quantitation and sequence fragments for identification. 
TopPIC was used for proteoform identification in which the TMT modification on lysine 
residues and N-termini is set as a fixed PTM.22 In total, 408 intact proteoforms from 95 
proteins were confidently identified and quantified from two LC-MS/MS runs after manual 
evaluation. Among them, 303 proteoforms were completely labeled (both at the N-terminus 
and at all lysine residues), while 64 proteoforms were labeled at all lysine residues with a 
missing label at the N-termini. The results demonstrate that the optimized proteoform-level 
TMT labeling platform can efficiently label and quantify intact proteoforms in complex 
samples.
VI. Opportunities and Challenges
While top-down proteomics offers unique advantages over bottom-up proteomics for its 
ability to identify proteoforms, technologies in the field are not as established or robust. In 
this section, we discuss several important remaining challenges in the field.
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False Discovery Rate and Characterization of Proteoforms
The false-discovery rate (FDR) determination in top-down proteomics is currently 
understudied, and there are two concepts of proteoform identification which are frequently 
conflated. The first is determining the FDR associated with a proteoform or protein 
identification, and the second is determining the extent to which a proteoform has been 
characterized.
Several top-down tools have implemented proteoform FDR estimation based on target-decoy 
strategies (e.g., TopPIC22, Informed Proteomics21, MetaMorpheus25, and TDPortal20). The 
proteoform identification FDR is the fraction of a set of identifications that are expected to 
be incorrect. Since FDR is a multiple testing correction, proteoform identification FDR is 
not a property of a single observation, but rather is a property of the complete set of 
observations. LeDuc et al. have recently shown that PrSM FDRs are not sufficient to control 
the FDR at either the proteoform or protein level.126 When reporting a PrSM FDR of 1%, 
the true proteoform FDR was several times higher; this discrepancy increases with larger 
study designs. The authors have provided a tool which will estimate proteoform-level FDR 
from the PrSM FDRs from any search tool.
The second problem is determining the extent of characterization of a proteoform given the 
available fragmentation data. The lack of complete overlap between detected proteoform 
fragment peaks and theoretical fragments requires reliance on a database to contain a faithful 
sequence representation of each proteoform in the sample. Some proteoforms consist of an 
identical set of amino acids but arranged in a different order (e.g., yeast histone proteins 
H2A.1 and H2A.2). These proteoforms have the same intact mass and share many fragment 
masses. However, only observation and identification of fragments from the portion of the 
proteoform with the distinguishing sequence facilitates definitive identification of the 
appropriate proteoform. The C-score was introduced as a score that indicates the level of 
characterization of a proteoform identification within a fully defined search space.127 Tools 
such as Informed Proteomics, MSPathFinder, MetaMorpheus, and the ProSight tools use 
prior knowledge of PTMs to narrow the search space for proteoform identification.
Sensitivity
Bottom-up proteomics yields higher-sensitivity for protein detection across the mass and 
concentration dimensions (Figure 4 and Supporting Figures S1 and S2). Proteoforms are 
digested into peptides, which have a uniformly low molecular weight and charge. As a 
result, mass spectra of peptides have fewer peaks as the ion current is distributed among 
fewer ion channels. Thus, the peaks have higher S/N ratios and fall well within the available 
scan range of most mass analyzers.16 Peptides also generally exhibit higher chromatographic 
resolution and are easier to fractionate, which results in delivery of peptides to the mass 
spectrometer at an optimal rate.128 The fractionation and identification of intact proteoforms 
is far more challenging. Intact proteoforms present solubility challenges that peptides do not 
possess. Membrane proteoforms, for instance, can have large regions of highly hydrophobic 
amino acids that span the cell membrane. These species are nearly insoluble in MS-
compatible buffers, whereas peptides are usually soluble.129 While there have been 
improvements in offline fractionation techniques to enhance solubility and decrease sample 
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complexity, as mentioned earlier, the resolution of online intact proteoform separations is 
still often not high enough to prevent co-elution of proteoforms.
Bottom-up proteomics also exhibits higher sensitivity than top-down proteomics because 
S/N decreases as a function of molecular weight.16 This translates to lower S/N and longer 
accumulation times in top-down analyses. Proteoforms can be hundreds of amino acids long 
and can fragment at multiple locations along the backbone, sometimes more than once, 
which generates internal fragment ions. Therefore, it is common for fragment ion signals to 
fall below detection limits. Techniques such as charge-reduction130 and ion-parking131–134 
have been used to simplify spectra and enhance sensitivity. However, sensitivity for 
identification of proteoforms diminishes severely beyond 30 kDa.16
Deconvolution
Precursor and fragment mass measurements of intact proteins are often complicated by 
complex isotope distributions. As mass increases, the relative abundance of the 
monoisotopic peak of any given multiplet inevitably decreases because the likelihood of 
observing a proteoform containing one or more heavy isotopes increases as the number of 
atoms in the proteoform increases (Figure 5). Isotopic deconvolution is the process of 
collecting an isotopic envelope’s peaks and determining its monoisotopic mass, charge, and 
summed intensity. Charge state deconvolution is the process of collecting all the isotopic 
envelopes of a proteoform in different charge states. These two processes are collectively 
referred to as deconvolution.
Proteomicists rely on deconvolution software for interpretation of mass spectra. Many 
deconvolution algorithms exist (e.g. THRASH135, MaxEnt136, MSDeconv137, Promex21, 
UniDec138), which can be divided into interpreting two categories of species: isotopically-
resolved and non-isotopically-resolved. The deconvolution of isotopically resolved species 
determines the charge of each species from the m/z spacing and intensity distribution of its 
isotopic peaks, while the deconvolution of non-isotopically-resolved species determines the 
charge from the m/z spacing between charge states and the charge state intensity 
distribution. Deconvolution usually takes place without the aid of a protein database. Such 
“blind” interpretation of mass spectra is prone to several types of errors, a few of which are 
highlighted here.
The monoisotopic peak is not visible in the spectrum for many large ions. The monoisotopic 
mass of the ion must then be inferred, typically by fitting the isotopic distribution to a model 
(e.g., averagine139). However, analytes with elemental compositions that differ greatly from 
the model and noise in the intensity measurements of each isotope peak result in fitting 
errors; i.e., an incorrect mass’s theoretical distribution fits better than the correct mass’s 
theoretical distribution. Errors in the monoisotopic mass inference occur from these 
incorrect fits and tend to scale in frequency and magnitude with analyte mass. These mass 
errors occur at multiples of approximately the mass of 13C minus 12C, because carbon is the 
dominant elemental component of proteins. Compensating for these mass errors by 
widening precursor or fragment mass tolerances increases the search space, which causes an 
increase in search time and FDR. Additionally, some modifications (e.g., deamidation) or 
Schaffer et al. Page 15
Proteomics. Author manuscript; available in PMC 2020 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
combinations of modifications (e.g., ammonia loss and oxidation) result in mass differences 
similar to monoisotopic mass errors, further exacerbating the problem.
A major difficulty for many deconvolution programs is the ability to discern electronic and 
chemical noise from an analytes’ true signal. Deconvolution algorithms routinely report 
masses that do not correspond to actual species, particularly when the spectrum quality is 
low. ProMex uses the proteoform elution profile to inform deconvolution and decrease the 
likelihood of random, non-reproducible masses being reported.21 However, the reporting of 
non-reproducible masses is still a major problem. This issue is especially problematic for 
software that identifies proteoforms from intact mass alone because false-positives are more 
likely without fragmentation spectra that provide additional evidence of an identification.
Proteoform Databases in Top-Down Searches
Proteomic analysis often relies on database searching to identify proteins. The completeness 
and accuracy of the protein database used is essential for obtaining high quality results. 
Canonical protein sequence databases for many organisms can be obtained from sources 
such as UniProt27, Ensembl140 or RefSeq141. While these databases are useful starting 
points for proteoform identification, they can be incomplete and can lack PTM or sequence 
information. Proteoforms present in a sample that lack a corresponding theoretical 
proteoform in the search database are challenging to identify. Experimental proteoforms are 
often first compared to theoretical proteoforms within a mass tolerance. If no match is 
found, then the search can be widened to include theoretical proteoforms with a different 
mass. However, one is still left with the problem of interpreting the mass difference. This 
can be especially difficult because the mass difference can result from a combination of 
sequence insertions, deletions, substitutions, truncations, PTMs, and deconvolution errors. 
These problems can be partially alleviated by using the spectral alignment algorithms in 
tools such as MSAlign+88, or by integrating proteogenomic data and bottom-up proteomic 
results to generate sample-specific databases.
Nucleic acid sequencing can reveal proteoform sequence changes that are absent in the 
canonical protein database. This field is known as proteogenomics. A general workflow for 
proteogenomic database generation follows: (i) Obtain nucleotide sequencing data. (ii) Align 
sequences to a reference genome if available or perform de novo alignment. (iii) Translate 
sequencing data to generate protein entries.142–149 The nucleotide sequencing data can be 
obtained from whole genome sequencing, exome sequencing, or RNA sequencing data. 
There has recently been an effort to develop software tools that facilitate the integration of 
genomics tools with proteomic analyses, including Spritz, ProteomeGenerator150 and the 
Galaxy-P System151.
An important factor to be considered when utilizing proteogenomic workflows is FDR. 
Incorporating variants into a protein database increases its size, and FDR increases with the 
number of proteoforms that are in the database but not in the sample. It is crucial to only 
annotate confidently identified variants to maintain a comprehensive but not inflated 
proteogenomic database.152
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Bottom-up data provides additional insights that can be used to improve proteoform 
identification. Novel PTMs identified in bottom-up can be annotated in a database for 
subsequent top-down analyses. For example, MetaMorpheus was recently used to generate 
an E. coli protein database annotated with novel PTMs.102 This database was used in a 
subsequent Proteoform Suite analysis, enabling proteoforms containing these PTMs to be 
identified. Additionally, the database can be filtered to contain only proteins confidently 
identified by bottom-up analysis. This filtering limits the search space, which decreases 
false-positives.
VII. A Vison for the Future
In any projection forward, it behooves one to be mindful of the admonition often attributed 
to Yogi Berra: “It’s hard to make predictions, especially about the future.” Nonetheless, it is 
possible to make some observations about likely paths.
Proteoform analysis today is limited primarily to the more abundant and lower molecular 
weight proteins. This offers a clear technical challenge to the community, wherein the future 
of proteoform analysis can evolve along two distinct axes: mass spectrometric, and “other”. 
In the arena of mass spectrometry, the standard analytical metrics of resolution, sensitivity, 
and speed all need to be improved for large proteins (e.g. >50 kDa). It is noteworthy that the 
fundamental limits of mass spectrometry are not at issue – there is no reason in principle that 
the accurate mass of a single ion of a large macromolecule cannot be measured. However, 
improvements in ionization sources, ion transfer efficiencies, and detector sensitivity are all 
needed to implement this on a routine basis for complex mixtures. One can imagine that one 
day, individual proteoform molecules will each have their accurate masses determined in 
rapid succession, simply counting them to determine their abundance.
It is also apparent that the gradual accrual of knowledge about proteoforms and proteoform 
families, immortalized in a comprehensive database or “proteoform atlas”, will allow the 
much more rapid and effective identification of proteoforms in the future. Proteomics can 
move from a “discovery” mode, involving complex data generation and interpretation, to a 
“scoring” mode, where proteoforms detected are matched up with members of a 
comprehensive proteoform database tailored for the sample under study. This strategy 
benefits greatly from a comprehensive approach to proteomics that integrates disparate data 
sources such as nucleotide sequence data, deep bottom-up data, and knowledge repositories 
such as UniProt and the CTDP Proteoform Repository.
Testing the biological consequences of individual proteoforms presents a remarkable 
challenge. Many contend that proteoforms are the ultimate biological actor. Yet, how one 
might introduce specific proteoforms into a biological context, or more challenging still, 
deliberately alter their concentration or localization for the purpose of understanding their 
role is still unclear. A grand challenge for the community would be to develop the power to 
synthesize specific proteoforms at will, fully defined with respect to PTM localization and 
amino acid backbone, and to introduce them into living systems. Even more challenging 
would be to be able to express such molecules at pre-defined locations (e.g., the cell nucleus 
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or the mitochondria) and/or times. Such capabilities would provide a tool of unprecedented 
power to reveal the functions of proteoforms.
On a longer horizon, a variety of exciting new single-molecule analysis platforms are 
actively under development around the world, including nanoscale cantilevers153, nanopore 
strategies154, interferometric light scattering155, cryo-electron microscopy156, x-ray 
scattering157 and others. The yet-to-be-determined and evolving strengths and limitations of 
such new strategies for proteoform identification will dictate how these approaches supplant 
or synergize with today’s technologies in ways that we cannot presently foresee.
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Figure 1. 
The sources of variation resulting in different proteoforms. Different proteoforms arising 
from the same gene make up a proteoform family.
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Figure 2. 
Top-down and bottom-up proteomics. In bottom-up proteomics, proteoforms are digested 
into peptides, resulting in loss of information about the original proteoform sequence and 
modifications.
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Figure 3. 
The yeast genes Rplp2 and YOL120C proteoform families visualized as a network of related 
proteoforms. Each circle represents a unique proteoform, including theoretical proteoforms 
(green), experimental proteoforms identified by MS/MS (purple), and experimental 
proteoforms observed in the MS1 spectra but unidentified by MS/MS (blue). Lines 
connecting circles represent mass differences corresponding to modifications. The size of 
blue circles is proportional to the integrated ion intensity.
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Figure 4. 
A plot of log10 intensity vs. log10 nominal mass for human Jurkat proteins identified using 
bottom-up proteomics. Proteins also identified by top-down analysis are marked in pink. 
Protein “nominal mass” is the mass of the full-length unmodified protein sequence from 
UniProt. For bottom-up, proteins are inferred from peptide sequences by MetaMorpheus; for 
top-down, proteins are identified from either the full-length sequence or a subsequence with 
TDPortal. The subset of proteins identified by top-down corresponds to the low molecular 
weight and highly abundant subset of the proteome.
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Figure 5. 
Theoretical isotopic envelopes of three species of different mass (870 Da, 4.3 kDa, and 21 
kDa). The monoisotopic mass of each species is annotated with an asterisk. The 
monoisotopic peak becomes increasingly difficult to observe as mass increases.
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Table 1.
Terms and definitions relevant to proteoform analysis.
Term Definition
Proteoform Defined sequence of amino acids with localized modifications
Proteoform Family All proteoforms derived from a single gene in a defined genome
Protein A linear sequence of amino acids
Protein Group A collection of proteins that are indistinguishable from each other based on the peptides identified in bottom-up 
analysis
Protein Isoform A member of a set of proteins from the same gene or gene family that arise from alternative splicing or variable 
promoter usage
Proteoform Spectrum Match An observed tandem mass spectrum match to a proteoform identification
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Table 2.
Summary of the intact protein separation techniques described in this review.
Separation Technique Mode of
Separation
Benefits Challenges
Gel-eluted liquid fraction entrapment 
electrophoresis (GELFrEE)
Size • High-resolution
• Commercially available
• MS-incompatible solvent
Serial Size Exclusion Chromatography Size • MS-compatible solvent • Lower resolution
• Sample load requirements
Reversed-Phase Liquid Chromatography Hydrophobicity • Small particle size and long 
columns increase peak capacity
• High and low pH are orthogonal 
for 2D-LC
• Requires in-house equipment and 
expertise to pack long, small-particle 
columns
• Some proteins difficult to elute
Capillary Zone Electrophoresis Electrophoretic
mobility
• Low sample amount needed • Low sample loading volume
• Narrow separation window
• Difficult to make high-quality 
capillary coatings
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Table 3.
Summary of proteoform identification software programs described in this review.
Software Program Key Features
MASH Suite http://ae.crb.wisc.edu/software.html Interface to perform MS/MS search and manually validate 
MS/MS identifications
MetaMorpheus
httD://aithub.com/smith-chem-wisc/MetaMorDheus
MS/MS search with PTM discovery and monoisotopic mass 
error notch search
MSPathFinder http://aithub.com/PNNL-Comp-Massspec/Informed-Proteomics/ MS/MS search that identifies proteoforms with sequence 
graph and uses LC-data integration to improve monoisotopic 
mass determination
Proteoform Suite http://aithub.com/smith-chem-wisc/ProteoformSuite MS1-onIy to identify proteoforms by intact-mass 
observations and mass differences corresponding to 
modifications
TDPortal
http://nrtdp.northwestern.edu/tdportal-request
MS/MS search against reference databases and biomarker 
search for truncated proteoforms
TopMG
http://proteomics.informatics.iupui.edu/software/toppic/
MS/MS tool for ultra-modified proteoforms
TopPIC
http://proteomics.informatics.iupui.edu/software/toppic/
MS/MS search against database with spectral alignment to 
determine unknown mass shifts
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